USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Megathura crenulata Post Larval Culture - Bottleneck for a…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
88247
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
0740238
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Stellar Biotechnologies, Inc.
332 E. Scott Street Port Hueneme, CA 93041
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: SBIR Phase I: Megathura crenulata Post Larval Culture - Bottleneck for a Valuable Medical Resource
Agency: NSF
Contract: 0740238
Award Amount: $94,633.00
 

Abstract:

This Small Business Innovation Research Phase I project develops methods for the reliable control of settlement and metamorphosis of larval stages of Megathura crenulata (the giant keyhole limpet) to support the production of commercial quantities of Keyhole Limpet Hemocyanin (KLH), a unique and medically valuable marine natural product. Unlike many other prospective medical products from marine organisms, KLH is already in extensive use as an immuno-stimulant, including in over 20 KLH-based clinical trials of therapeutic vaccines. KLH is commonly produced from animals harvested from the finite and fragile natural populations of California and Northern Baja California. With the potential success of one or more of these KLH-based cancer vaccines, the commercial market for KLH could exceed $50 million and place extreme pressure on the species. The broader impacts of this research are significant to the development of new medicines and the preservation of a threatened marine species. Therapeutic vaccines are a promising new class of treatment for cancer, arthritis, and other debilitating chronic diseases; several of these vaccines rely on the proven safety and efficacy of KLH?s immuno-stimulatory properties for their therapeutic effects. Although the natural population of M. crenulata cannot sustain the quantities of KLH required for commercial vaccine products, aquaculture technology has the potential to overcome this supply constraint. Reliable methods for controlling the larval stages of the M. crenulata life cycle are the key to large-scale aquaculture, and could eliminate the biomedical industry?s dependence on wild-harvested animals for commercial KLH supplies.

Principal Investigator:

Frank R. Oakes
BS
8054882147
foakes@stellarbiotech.com

Business Contact:

Frank R. Oakes
BS
8054882147
foakes@stellarbiotech.com
Small Business Information at Submission:

Stellar Biotechnologies, Inc.
417 E. Hueneme Rd. PMB #170 Port Hueneme, CA 93041

EIN/Tax ID: 770522411
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No